Takeda Pharmaceutical : FY2023 (April 2023-March 2024) Quarter 4 Quarterly Highlights Infographic

FY2023 Financial Results

FY2023 Update

3 new drug approvals

from the U.S. FDA

And multiple life-cycle management approvals in FY2023

FY2023 Financial Results

Revenue

¥4,263.8B

+1.5% growth at CER +5.9% growth at AER

FY2023 Financial Results

Core Operating Profit	Core Operating	Reported Operating
	Profit Margin	Profit

¥1,054.9B 24.7% ¥214.1B

-13.3% change at Constant Exchange Rate (CER) / -11.2% at Actual Exchange Rate (AER) reflects generic impact and increased investment in R&D and data & technology

-56.4% change at Actual Exchange Rate impacted by non-core items

FY2023 Financial Results

Our extensive portfolio of

Growth & Launch Products continued to drive revenue growth.

43%

Share of Total Revenue

+12.8%

Growth at CER

FY2024 Outlook Highlights

50 million doses of dengue vaccine

to be manufactured per year in partnership with Biological E. Ltd.

Accelerating our goal to manufacture 100 million doses per year by 2030

FY2024 Outlook Highlights

Up to 6 potential new therapies

expected in Phase 3 development in FY2024

FY2024 Full-Year Outlook

Continued momentum of Growth & Launch Products expected to mitigate remaining loss of exclusivity headwinds

Core Revenue	Core Operating Profit
¥4,350.0B	B
	¥1,000.0

Management Guidance at CER
Core Revenue	Core Operating Profit
Flat to slightly	Approximately
declining	10% decline

Core EPS

¥431

Core EPS

Mid-10s% decline

This presentation contains forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations. For more information about our use of forward-looking statements, including important cautionary language, see Takeda's FY2023 investor presentation (available at https://www.takeda.com/investors/financial-results/quarterly-results/), which is hereby incorporated by reference. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CER (Constant Exchange Rate) change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating Reported or Core results for the current period using corresponding exchange rates in the same period of the previous fiscal year.

Core Revenue, Core Operating Profit, Core Operating Profit Margin, Core EPS, CER % Change, Net Debt, Adjusted EBITDA, and Free Cash Flow are Non-IFRS measures, i.e., measures not calculated and presented in accordance with IFRS. See the financial appendix at the end of Takeda's FY2023 investor presentation (available at https://www.takeda.com/investors/financial-results/quarterly-results/ ) for further information about Takeda's Non-IFRS Measures and reconciliations to the most directly comparable measures calculated and presented in accordance with IFRS.